Targeting calpain-mediated proteolysis and peptide signaling as a strategy to reduce injury in multiple sclerosis.
University of North Dakota School of Medicine and Health Sciences, Department of Basic Sciences, Grand Forks, North Dakota.
Thad A
TA
Rosenberger
D000818:Animals; D002154:Calpain / Q000037:antagonists & inhibitors*; D002219:Carbamates / Q000494:pharmacology*; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology*; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy*; D056747:Immunomodulation / Q000187:drug effects*; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009410:Nerve Degeneration / Q000188:drug therapy*
C515164:((1S)-1-((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester; D002219:Carbamates; D015853:Cysteine Proteinase Inhibitors; D002154:Calpain